@article{APS7053,
author = {Si-sun XU and Zhi-xu GAO and Zheng WENG and Zun-ming DU and Wei-an XU and Jian-shen YANG and Ming-lian ZHANG and Zhen-hua TONG and Yong-sheng FANG and Xin-sheng CHAI and Shu-lan LI},
title = {Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease},
journal = {Acta Pharmacologica Sinica},
volume = {16},
number = {5},
year = {2016},
keywords = {},
abstract = {AIM:
To evaluate the efficacy and safety of tablet huperzine-A (Hup) in patients with Alzheimer's disease.
METHODS:
Using multicenter, prospective, double-blind, parallel, placebo controlled and randomized method, 50 patients were administered orally 0.2 mg (4 tablets) Hup and 53 patients were given po 4 tablets of placebo bid for 8 wk. All patients were evaluated with Wechsler memory scale, Hasegawa dementia scale, mini-mental state examination scale, activity of daily living scale, treatment emergency symptom scale, and measured with BP, HR, ECG, EEG, ALT, AKP, BUN, Cr, Hb, WBC, and urine routine.
RESULTS:
About 58% (29/50) of patients treated with Hup showed improvements in their memory (P < 0.01), cognitive (P < 0.01), and behavioral (P < 0.01 functions. The efficacy of Hup was better than placebo (36%, 19/53) (P < 0.05). No severe side effect was found.
CONCLUSION:
Hup is a promising drug for symptomatic treatment of Alzheimer's disease},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/7053}
}